This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Weber-Schoendorfer, C Articles by Schaefer, C PubMed PubMed Citation Articles by Weber-Schoendorfer, C Articles by Schaefer, C Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Birth Defects High Risk Pregnancy Multiple Sclerosis Pregnancy Loss Social Bookmarking                         What's this?

Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study

Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin, Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Berliner Betrieb für Zentrale Gesundheitliche Aufgaben, Berlin, Germanyschaefer{at}embryotox.de

C Schaefer

Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin, Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Berliner Betrieb für Zentrale Gesundheitliche Aufgaben, Berlin, Germany

Background

There is still uncertainty about the management of pregnant women exposed to immunomodulatory therapy for treatment of multiple sclerosis (MS) in pregnancy.

Objective

To assess the safety of interferon (IFN)-β1a, IFN-β1b, and glatiramer acetate (GA) for treatment of MS during pregnancy.

Methods

A prospective observational cohort study was performed with patients enrolled through a drug risk assessment by the Teratology Information Service (TIS), Berlin, from 1996 to 2007. Pregnancy outcomes for four groups of women were compared: two exposed groups (IFN, n = 69; GA, n = 31), MS patients without exposure to IFN or GA (n = 64) and a healthy comparative group (n = 1556).

Results

Spontaneous abortion rates were in normal range for all groups except the small subgroup of IFN-β1b exposed (n = 21), where 28% aborted spontaneously. There were two major birth defects in the GA group (club feet and atrioventricular canal) and none in the IFN cohort. Preterm delivery was not significantly different between exposed cohorts and healthy controls. The adjusted mean birth weight was in normal range in all groups (>3200 g), but newborns exposed to IFN had a significantly lower birth weight.

Conclusion

Our findings suggest that neither GA nor IFN constitutes a major risk for prenatal developmental toxicity.

Key Words: abnormalities • drug-induced • cohort study • glatiramer acetate • interferon beta • multiple sclerosis • pregnancy • pregnancy outcome

Multiple Sclerosis, Vol. 15, No. 9, 1037-1042 (2009)
DOI: 10.1177/1352458509106543


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?